Basic and diluted earnings per share for the three months ended March 31, 2022 and 2021, respectively consisted of the following (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2022 |
|
|
2021 |
|
Numerator (Basic and Diluted): |
|
|
|
|
|
|
|
|
Net income |
|
$ |
32,783 |
|
|
$ |
15,012 |
|
Change in value for stock settled consideration |
|
|
(63 |
) |
|
|
12 |
|
|
|
|
|
|
|
|
|
|
Adjusted net income |
|
$ |
32,720 |
|
|
$ |
15,024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares issued and outstanding |
|
|
39,721 |
|
|
|
39,432 |
|
|
|
|
(13 |
) |
|
|
(17 |
) |
|
|
|
281 |
|
|
|
342 |
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
39,989 |
|
|
|
39,757 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per common share |
|
$ |
0.82 |
|
|
$ |
0.38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding from above |
|
|
39,989 |
|
|
|
39,757 |
|
Add: Dilutive effect of RSUs, RSAs & ESPP |
|
|
396 |
|
|
|
208 |
|
Add: Contingently issuable shares
|
|
|
89 |
|
|
|
159 |
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
40,474 |
|
|
|
40,124 |
|
|
|
|
|
|
|
|
|
|
Diluted earnings per common share |
|
$ |
0.81 |
|
|
$ |
0.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Antidilutive shares excluded from diluted earnings per common share
|
|
|
778 |
|
|
|
230 |
|
|
|
|
|
|
|
|
|
|
|
RSAs were issued and outstanding to the non-employee directors and have a one-year vesting term subject to service requirements. See Note 10 – “Stock-Based Compensation Plans” for additional information. |
|
Shares are included in weighted average common shares outstanding as the shares are fully vested but have not yet been delivered. See Note 10 – “Stock-Based Compensation Plans” for additional information. |
|
Relates to contingently issuable stock settled consideration. |
|
Primarily pertaining to RSU grants to the Company’s employees and independent contractors. |
|